Zaltoprofen (JAN; trade name Soleton) is a nonsteroidal anti-inflammatory drug (NSAID) used as an analgesic, antipyretic, and anti-inflammatory agent.[1] It is a selective COX-2 inhibitor and also inhibits bradykinin-induced pain responses without blocking bradykinin receptors.[2]

Zaltoprofen
Clinical data
Trade namesSoleton
Other namesZaxoprofen
Drug classNSAID
Legal status
Legal status
  • US: Not FDA approved
  • Japan: Rx-only
Identifiers
  • 2-(6-Oxo-5H-benzo[b][1]benzothiepin-3-yl)propanoic acid
CAS Number
PubChem CID
DrugBank
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.070.863 Edit this at Wikidata
Chemical and physical data
FormulaC17H14O3S
Molar mass298.36 g·mol−1
3D model (JSmol)
  • CC(C1=CC2=C(C=C1)SC3=CC=CC=C3C(=O)C2)C(=O)O

It was approved for use in Japan in 1993.[3]

References

edit
  1. ^ "Zaltoprofen". drugs.com.
  2. ^ Hirate K, Uchida A, Ogawa Y, Arai T, Yoda K (April 2006). "Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors". Neuroscience Research. 54 (4): 288–94. doi:10.1016/j.neures.2005.12.016. PMID 16473424. S2CID 27367042.
  3. ^ "Zaltoprofen Launched in Japan". thepharmaletter.com. September 20, 1993.